EU-US-Japanese-Indian Pharmacopeia Group Says ‘New Members Wanted’

The deadline is nearing for pharmacopoeias to express their interest in joining the decades-old discussion group that works to harmonize excipient monographs and general chapters and reduce the burden on manufacturers to perform analytical procedures in different ways depending on the jurisdiction.

The PDG is working to harmonize excipient monographs and general chapters in pharmacopoeias around the world • Source: Shutterstock

Pharmacopoeias wishing to join the 35 year-old discussion group focused on harmonizing pharmacopoeial standards globally have until 15 September to express their interest and 31 December to submit a formal application.

Key Takeaways

  • The Pharmacopoeial Discussion Group has launched the next phase of its global expansion initiative aimed at increasing convergence of harmonized pharmacopoeial standards. 

  • Pharmacopoeias around the world that want to join the PDG have until 15 September to express their interest and 31 December to submit a formal application

The Pharmacopoeial Discussion Group, which was founded in1989 by the pharmacopoeias in Europe, Japan and the US and was joined by the Indian Pharmacopoeia Commission (IPC) last year, wants to hear from other

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from International

More from Geography

EU Shaping Biotech Act To Unleash SME Potential

 

European companies, in particular small and midsize enterprises, spin-offs and start-ups have a hard time expanding within the single market “because of a complex regulatory framework that is perceived as slow and burdensome,” according to the European Commission.

New EU Filings

 

Brensocatib, Insmed's investigational treatment for non-cystic fibrosis bronchiectasis, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

‘Tectonic’ Arkansas PBM Legislation May Upend Industry

 
• By 

Industry will fight hard to prevent other states or the federal government from adopting measures similar to Arkansas' law preventing PBMs from owning pharmacies.